Effect of zatebradine on contractility, relaxation and coronary blood flow

Jeffrey Breall, Jun Watanabe, William Grossman

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives. The purpose of this study was to compare the effects of zatebradine on heart rate, contractility and relaxation with those of its structural analog verapamil. We used isoproterenol, a potent beta-agonist, to see how these effects were modulated by sympathetic activation. We also compared the effects of zatebradine and verapamil on coronary blood flow and coronary blood flow reserve. Background. Zatebradine, previously called UL-FS 49, is a new bradycardic agent believed to act selectively at the sinoatrial node. Methods. Isolated isovolumetric pig hearts were prepared and left ventricular pressure, its first derivative (dP/dt), tau and heart rate were measured both before and after administration of either 0.975 mg of zatebradine (Group I, n = 8) or 125 μg of verapamil (Group II, n = 8). After the effects of each drug reached a plateau, a continuous infusion of isoproterenol was started and measurements were obtained again and compared with a third group of measurements from control hearts infused with isoproterenol after receiving only saline solution (n = 8). We also assessed the effects of zatebradine and verapamil on coronary vascular tone by measuring flow in the left anterior descending coronary artery in intact anesthetized open chest pigs both before and after the Intracoronary administration of these drugs (n = 8 for each). All preparations were atrially paced to negate any bradycardic effects of the drugs. Results. In the group that received zatebradine, mean (±SE) heart rate decreased from 143 ± 8 to 99 ± 4 beats/min (p <0.01) and there was no significant change in either peak left veatricular systolic pressure, dP/dt or tau. In contrast, verapamil produced a lesser decrease in heart rate (136 ± 7 to 120 ± 7 beats/min, p <0.05) but produced substantial decreases in peak left ventricular pressure (100 ± 3 to 45 ± 4 mm Hg, p <0.01) and dP/dt (68% decrease, p <0.01) and an increase in tau (+26%, p <0.05). Isoproterenol restored these variables toward normal values in the hearts treated with verapamil, although left vestricular systolic pressure and dP/dt were restored to control values only at the highest isoproterenol concentrations. In the hearts treated with zatebradine, isoproterenol sagnificantly increased left ventricular pressure and contractility and decreased tau; however, beast rate remained unchanged at peak effect. Zatebradine had no effect on coronary blood flow and there was a 100% increase in flow with reactive heyperemia, Conversely, verapamil increased coromry flow by 100%, with no subsequent further increase by reactive hyperemia compared with control values. Conclusions. Although structurally similar to verapamil, zatebradine is a nighty specific bradycardic agent. It has little direct effect on left ventricular developed pressare, contractility, relaxation and coronary vascular tone. Furthermore, the bradycardic effect of zatebradine unlike that of verapamil, is not overcome by doses of isoproterenol that increase developed pressure and contractility and improve relaxation. Because of its highly specific bradycardic effect, this drug may potentially be useful in treating patients with ischemic heart disease or congestive heart failure.

Original languageEnglish (US)
Pages (from-to)471-477
Number of pages7
JournalJournal of the American College of Cardiology
Volume21
Issue number2
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Verapamil
Isoproterenol
Ventricular Pressure
Heart Rate
Pharmaceutical Preparations
Blood Vessels
zatebradine
Swine
Blood Pressure
Myocardial Contraction
Sinoatrial Node
Hyperemia
Sodium Chloride
Myocardial Ischemia
Coronary Vessels
Reference Values
Thorax
Heart Failure
Pressure
Control Groups

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Effect of zatebradine on contractility, relaxation and coronary blood flow. / Breall, Jeffrey; Watanabe, Jun; Grossman, William.

In: Journal of the American College of Cardiology, Vol. 21, No. 2, 1993, p. 471-477.

Research output: Contribution to journalArticle

@article{13c934494c764f228a617f0840ceb914,
title = "Effect of zatebradine on contractility, relaxation and coronary blood flow",
abstract = "Objectives. The purpose of this study was to compare the effects of zatebradine on heart rate, contractility and relaxation with those of its structural analog verapamil. We used isoproterenol, a potent beta-agonist, to see how these effects were modulated by sympathetic activation. We also compared the effects of zatebradine and verapamil on coronary blood flow and coronary blood flow reserve. Background. Zatebradine, previously called UL-FS 49, is a new bradycardic agent believed to act selectively at the sinoatrial node. Methods. Isolated isovolumetric pig hearts were prepared and left ventricular pressure, its first derivative (dP/dt), tau and heart rate were measured both before and after administration of either 0.975 mg of zatebradine (Group I, n = 8) or 125 μg of verapamil (Group II, n = 8). After the effects of each drug reached a plateau, a continuous infusion of isoproterenol was started and measurements were obtained again and compared with a third group of measurements from control hearts infused with isoproterenol after receiving only saline solution (n = 8). We also assessed the effects of zatebradine and verapamil on coronary vascular tone by measuring flow in the left anterior descending coronary artery in intact anesthetized open chest pigs both before and after the Intracoronary administration of these drugs (n = 8 for each). All preparations were atrially paced to negate any bradycardic effects of the drugs. Results. In the group that received zatebradine, mean (±SE) heart rate decreased from 143 ± 8 to 99 ± 4 beats/min (p <0.01) and there was no significant change in either peak left veatricular systolic pressure, dP/dt or tau. In contrast, verapamil produced a lesser decrease in heart rate (136 ± 7 to 120 ± 7 beats/min, p <0.05) but produced substantial decreases in peak left ventricular pressure (100 ± 3 to 45 ± 4 mm Hg, p <0.01) and dP/dt (68{\%} decrease, p <0.01) and an increase in tau (+26{\%}, p <0.05). Isoproterenol restored these variables toward normal values in the hearts treated with verapamil, although left vestricular systolic pressure and dP/dt were restored to control values only at the highest isoproterenol concentrations. In the hearts treated with zatebradine, isoproterenol sagnificantly increased left ventricular pressure and contractility and decreased tau; however, beast rate remained unchanged at peak effect. Zatebradine had no effect on coronary blood flow and there was a 100{\%} increase in flow with reactive heyperemia, Conversely, verapamil increased coromry flow by 100{\%}, with no subsequent further increase by reactive hyperemia compared with control values. Conclusions. Although structurally similar to verapamil, zatebradine is a nighty specific bradycardic agent. It has little direct effect on left ventricular developed pressare, contractility, relaxation and coronary vascular tone. Furthermore, the bradycardic effect of zatebradine unlike that of verapamil, is not overcome by doses of isoproterenol that increase developed pressure and contractility and improve relaxation. Because of its highly specific bradycardic effect, this drug may potentially be useful in treating patients with ischemic heart disease or congestive heart failure.",
author = "Jeffrey Breall and Jun Watanabe and William Grossman",
year = "1993",
doi = "10.1016/0735-1097(93)90691-S",
language = "English (US)",
volume = "21",
pages = "471--477",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Effect of zatebradine on contractility, relaxation and coronary blood flow

AU - Breall, Jeffrey

AU - Watanabe, Jun

AU - Grossman, William

PY - 1993

Y1 - 1993

N2 - Objectives. The purpose of this study was to compare the effects of zatebradine on heart rate, contractility and relaxation with those of its structural analog verapamil. We used isoproterenol, a potent beta-agonist, to see how these effects were modulated by sympathetic activation. We also compared the effects of zatebradine and verapamil on coronary blood flow and coronary blood flow reserve. Background. Zatebradine, previously called UL-FS 49, is a new bradycardic agent believed to act selectively at the sinoatrial node. Methods. Isolated isovolumetric pig hearts were prepared and left ventricular pressure, its first derivative (dP/dt), tau and heart rate were measured both before and after administration of either 0.975 mg of zatebradine (Group I, n = 8) or 125 μg of verapamil (Group II, n = 8). After the effects of each drug reached a plateau, a continuous infusion of isoproterenol was started and measurements were obtained again and compared with a third group of measurements from control hearts infused with isoproterenol after receiving only saline solution (n = 8). We also assessed the effects of zatebradine and verapamil on coronary vascular tone by measuring flow in the left anterior descending coronary artery in intact anesthetized open chest pigs both before and after the Intracoronary administration of these drugs (n = 8 for each). All preparations were atrially paced to negate any bradycardic effects of the drugs. Results. In the group that received zatebradine, mean (±SE) heart rate decreased from 143 ± 8 to 99 ± 4 beats/min (p <0.01) and there was no significant change in either peak left veatricular systolic pressure, dP/dt or tau. In contrast, verapamil produced a lesser decrease in heart rate (136 ± 7 to 120 ± 7 beats/min, p <0.05) but produced substantial decreases in peak left ventricular pressure (100 ± 3 to 45 ± 4 mm Hg, p <0.01) and dP/dt (68% decrease, p <0.01) and an increase in tau (+26%, p <0.05). Isoproterenol restored these variables toward normal values in the hearts treated with verapamil, although left vestricular systolic pressure and dP/dt were restored to control values only at the highest isoproterenol concentrations. In the hearts treated with zatebradine, isoproterenol sagnificantly increased left ventricular pressure and contractility and decreased tau; however, beast rate remained unchanged at peak effect. Zatebradine had no effect on coronary blood flow and there was a 100% increase in flow with reactive heyperemia, Conversely, verapamil increased coromry flow by 100%, with no subsequent further increase by reactive hyperemia compared with control values. Conclusions. Although structurally similar to verapamil, zatebradine is a nighty specific bradycardic agent. It has little direct effect on left ventricular developed pressare, contractility, relaxation and coronary vascular tone. Furthermore, the bradycardic effect of zatebradine unlike that of verapamil, is not overcome by doses of isoproterenol that increase developed pressure and contractility and improve relaxation. Because of its highly specific bradycardic effect, this drug may potentially be useful in treating patients with ischemic heart disease or congestive heart failure.

AB - Objectives. The purpose of this study was to compare the effects of zatebradine on heart rate, contractility and relaxation with those of its structural analog verapamil. We used isoproterenol, a potent beta-agonist, to see how these effects were modulated by sympathetic activation. We also compared the effects of zatebradine and verapamil on coronary blood flow and coronary blood flow reserve. Background. Zatebradine, previously called UL-FS 49, is a new bradycardic agent believed to act selectively at the sinoatrial node. Methods. Isolated isovolumetric pig hearts were prepared and left ventricular pressure, its first derivative (dP/dt), tau and heart rate were measured both before and after administration of either 0.975 mg of zatebradine (Group I, n = 8) or 125 μg of verapamil (Group II, n = 8). After the effects of each drug reached a plateau, a continuous infusion of isoproterenol was started and measurements were obtained again and compared with a third group of measurements from control hearts infused with isoproterenol after receiving only saline solution (n = 8). We also assessed the effects of zatebradine and verapamil on coronary vascular tone by measuring flow in the left anterior descending coronary artery in intact anesthetized open chest pigs both before and after the Intracoronary administration of these drugs (n = 8 for each). All preparations were atrially paced to negate any bradycardic effects of the drugs. Results. In the group that received zatebradine, mean (±SE) heart rate decreased from 143 ± 8 to 99 ± 4 beats/min (p <0.01) and there was no significant change in either peak left veatricular systolic pressure, dP/dt or tau. In contrast, verapamil produced a lesser decrease in heart rate (136 ± 7 to 120 ± 7 beats/min, p <0.05) but produced substantial decreases in peak left ventricular pressure (100 ± 3 to 45 ± 4 mm Hg, p <0.01) and dP/dt (68% decrease, p <0.01) and an increase in tau (+26%, p <0.05). Isoproterenol restored these variables toward normal values in the hearts treated with verapamil, although left vestricular systolic pressure and dP/dt were restored to control values only at the highest isoproterenol concentrations. In the hearts treated with zatebradine, isoproterenol sagnificantly increased left ventricular pressure and contractility and decreased tau; however, beast rate remained unchanged at peak effect. Zatebradine had no effect on coronary blood flow and there was a 100% increase in flow with reactive heyperemia, Conversely, verapamil increased coromry flow by 100%, with no subsequent further increase by reactive hyperemia compared with control values. Conclusions. Although structurally similar to verapamil, zatebradine is a nighty specific bradycardic agent. It has little direct effect on left ventricular developed pressare, contractility, relaxation and coronary vascular tone. Furthermore, the bradycardic effect of zatebradine unlike that of verapamil, is not overcome by doses of isoproterenol that increase developed pressure and contractility and improve relaxation. Because of its highly specific bradycardic effect, this drug may potentially be useful in treating patients with ischemic heart disease or congestive heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0027516071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027516071&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(93)90691-S

DO - 10.1016/0735-1097(93)90691-S

M3 - Article

VL - 21

SP - 471

EP - 477

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -